- Home
- TSEM vs BBIO Comparison
TSEM vs BBIO Comparison
Compare TSEM & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSEM
- BBIO
- Stock Information
- Founded
- TSEM 1993
- BBIO 2015
- Country
- TSEM Israel
- BBIO United States
- Employees
- TSEM N/A
- BBIO N/A
- Industry
- TSEM Semiconductors
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- TSEM Technology
- BBIO Health Care
- Exchange
- TSEM Nasdaq
- BBIO Nasdaq
- Market Cap
- TSEM 8.3B
- BBIO 9.4B
- IPO Year
- TSEM 1994
- BBIO 2019
- Fundamental
- Price
- TSEM $74.37
- BBIO $55.10
- Analyst Decision
- TSEM Strong Buy
- BBIO Strong Buy
- Analyst Count
- TSEM 4
- BBIO 16
- Target Price
- TSEM $68.25
- BBIO $64.44
- AVG Volume (30 Days)
- TSEM 926.2K
- BBIO 2.2M
- Earning Date
- TSEM 11-10-2025
- BBIO 11-11-2025
- Dividend Yield
- TSEM N/A
- BBIO N/A
- EPS Growth
- TSEM N/A
- BBIO N/A
- EPS
- TSEM 1.74
- BBIO N/A
- Revenue
- TSEM $1,487,934,000.00
- BBIO $235,812,000.00
- Revenue This Year
- TSEM $10.78
- BBIO $115.46
- Revenue Next Year
- TSEM $12.76
- BBIO $65.03
- P/E Ratio
- TSEM $42.20
- BBIO N/A
- Revenue Growth
- TSEM 7.18
- BBIO 7.62
- 52 Week Low
- TSEM $28.64
- BBIO $21.72
- 52 Week High
- TSEM $76.86
- BBIO $57.49
- Technical
- Relative Strength Index (RSI)
- TSEM 63.32
- BBIO 58.02
- Support Level
- TSEM $70.91
- BBIO $52.97
- Resistance Level
- TSEM $76.00
- BBIO $57.48
- Average True Range (ATR)
- TSEM 2.90
- BBIO 1.66
- MACD
- TSEM -0.44
- BBIO 0.15
- Stochastic Oscillator
- TSEM 65.75
- BBIO 65.02
About TSEM Tower Semiconductor Ltd.
Tower Semiconductor Ltd is a pure-play specialty foundry that manufactures semiconductors. As a pure-play foundry, it focuses on producing integrated circuits (ICs), based on the design specifications of customers. The company's line of integrated circuits is incorporated into a range of products and markets, including consumer electronics, personal computers, communications, automotive, and industrial and medical device products. It produces ICs alongside wholly-owned subsidiaries through fabrication facilities located in Japan. The company has a geographical presence in the USA, Japan, Asia (other than Japan), and Europe.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.